after close1 source ↓written by the desknot a recommendation
NATCO Pharma reported Q3FY26 revenue of ₹7,054 Mn, up from ₹6,511 Mn YoY. The net profit reached ₹1,513 Mn, with an EPS of ₹8.46. Key developments include the launch of Risdiplam and a strategic acquisition in Adcock Ingram Holdings. This performance may enhance investor confidence and market sentiment.
Not investment advice. For informational purposes only.
OI Charts is not a SEBI-registered investment adviser or research analyst. This bulletin was written by the OI Charts desk from the public sources listed here. It is commentary on market conditions, not a basis for any investment decision and not a recommendation to buy or sell any security. Prices as of 12 Feb 2026, 16:05 IST.
Sourcesnews.google.com
The market after the news
Bulletin at 16:05 IST on 12 Feb 2026. Every change is measured from ₹839.85, the last close before it, on 12 Feb. Nifty 50 is measured over the same sessions.
| Session | Close ₹ | Change % | Nifty % |
|---|---|---|---|
| Before12 Feb | ₹839.85 | base | base |
| On the day13 Feb | ₹823.85 | ▼ −1.9% | ▼ −1.3%−0.6 pp difference |
| +1 session16 Feb | ₹881.45 | ▲ +5.0% | ▼ −0.5%+5.4 pp difference |
| +3 sessions18 Feb | ₹890.50 | ▲ +6.0% | ▲ +0.1%+6.0 pp difference |
| +5 sessions20 Feb | ₹891.70 | ▲ +6.2% | ▼ −0.9%+7.1 pp difference |
Source NSE UDiFF bhavcopy · NATCOPHARM on the desk →